Innorna

Innorna is a leading biotechnology research company dedicated to delivering programmable medicines for everyone. Founded in 2019, Innorna is committed to developing state-of-the-art LNP delivery systems and RNA therapies to address unmet medical needs. The company’s innovative mRNA-LNP platform has facilitated the construction of a robust pipeline targeting infectious diseases, rare diseases, metabolic disorders, and cancer immunotherapy.

Innorna's proprietary Diversity-Oriented Lipid Library, featuring over 6,000 ionizable lipids, enables breakthroughs in innovative RNA medicines, including mRNA vaccines and therapeutics. Located at Rm 222, 12 W Science and Technology West Avenue, Phase 3, HKSTP, Shatin, HKSAR, Hong Kong, Innorna not only focuses on internal R&D efforts but also collaborates with global-leading biotechnology partners to expand the reach of its transformative technology.

With a commitment to innovation and addressing critical medical challenges, Innorna continues to solidify its position as a key player in the biotechnology landscape. Investors and industry peers have recognized Innorna with accolades such as Forbes China Industry Leaders, MIT Technology Review’s 50 Smartest Companies, and Fortune China Impact Startups.

We invite the manager of Innorna to create a customized and exclusive company showcase and product listing on our platform.